viewBATM Advanced Communications Ltd

BATM Advanced Comm - BATM receives c. $31m order to produce ventilators

RNS Number : 4152K
BATM Advanced Communications Ld
22 April 2020

LEI: 213800FLQUB9J289RU66

22 April 2020


BATM Advanced Communications Limited

("BATM" or "the Group")


BATM receives c. $31 million order to produce ventilators in response to COVID-19

Order awarded by a European government for 1,000 ventilators to be delivered this year


BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that it has received a €29 million (c. $31 million) order for the delivery of 1,000 critical care mechanical ventilators to a European government. The Group has received an upfront fee of €7.25 million and expects the balance to be paid on completion of delivery in the second half of 2020.


The ventilator, which is suitable for infants through to adults, is aimed at Intensive Care Unit environments for patients suffering from SARS-CoV-2 (COVID-19). It is a high-performance ventilator, with features such as spontaneous breathing modes to enable synchronisation with a patient's breathing, and it has already received full CE certification with further certifications pending.


Production is commencing immediately with up to approximately 25% of the ventilators expected to be delivered in the first half and the remainder in the third quarter of the year. It is being manufactured by the Group's Celitron subsidiary in Hungary, which has been producing equipment for medical environments globally for over 10 years.


In addition, further to the announcements of 27 February and 19 March 2020, the Group is pleased to report progress with its COVID-19 diagnostic kits. The Group has continued to ramp up delivery of its kits that are for use by medical facilities and the development of its kit for home-use, in partnership with Novamed, is on track to be completed within the next three months as planned.


Dr Zvi Marom, Chief Executive Officer of BATM, said: "Since the beginning of the SARS-CoV-2 (COVID-19) outbreak, our bio-medical businesses have been active in seeking solutions to support the global response. We are now able to offer a critical care ventilator alongside our diagnostic products, which are all high-performing solutions that we continue to innovate and improve. This is a significant order, which we expect to expand, and we are proud that we will be able to make a difference to the lives of so many people who are fighting this virus. We are continuing to dedicate the efforts of our bio-medical businesses to help public health authorities combat this pandemic as well as to provide solutions to support them in the aftermath."         



BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525                 

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury, Rachel So

+44 20 7618 9100


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: BATM Advanced Communications Ltd

Price: 123

Market: LSE
Market Cap: £541.54 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



BATM Advanced Communications 'overwhelmed by demand' for its coronavirus tests

BATM Advanced Communications Limited's (LON:BVC) Zvi Marom speaks to Proactive London's Andrew Scott after hiking its full-year revenue and earnings expectations. He says the Bio-Medical division has performed exceptionally well in the first half of 2020, thanks in part to the sale of antigen...

2 weeks, 1 day ago